2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3097

Osteoclast Precursor Frequency and Imaging Findings Associated with Arthritis Onset in a Psoriasis Longitudinal Cohort
Abstract Number: 365

Osteonecrosis of the Femoral Head Is Associated with Low Bone Mass.
Abstract Number: 357

Osteoporosis and Breast Cancer: Outcomes at a Specialized Osteoporosis Clinic Following a Structured Assessment
Abstract Number: 1796

Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 360

Osteoporosis Prevalence in Lung Transplant Patients
Abstract Number: 356

Osteoporotic Fracture As the Main Risk Factor in the Detection of Osteoporosis in Men Under 70 Years
Abstract Number: 1507

Our Strategy of Preventing Tuberculosis (TB) in Patients with Rheumatic Diseases Under the Treatment with Biologic Dmards
Abstract Number: 1386

Outcome of 847 Childhood-Onset Systemic LUPUS Erythematousus Patients in Three Age Groups
Abstract Number: 972

Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study
Abstract Number: 2799

Outcomes in Patients with Early and Delayed Onset Lupus Nephritis
Abstract Number: 2805

Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment
Abstract Number: 21

Outcomes of Rheumatoid Arthritis Patients with Hip Fracture
Abstract Number: 7L

Overall Reduction in Acute Flares during Treatment with Febuxostat Compared with Placebo over 2 Years in Patients with Early Gout
Abstract Number: 2870

Overexpression of EZH2 at the microRNA-142 Regulatory Region Contributes to Down-Regulation of microRNA-142-3p/5p in Systemic Lupus Erythematosus
Abstract Number: 798

Oxidized Phospholipids,Lipoprotein(a) and Glycosphingolipid Associated B-1,4 Galactosyltransferase in a Johns Hopkins Cohort of Patients with Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].